Furiex Pharmaceuticals, Inc. recently declared that the European Commission endorsed the optimistic opinion adopted by the Committee for Human Medicinal Products (CHMP) on October 18, 2011 for Priligy(TM) (dapoxetine) 30 mg and 60 mg doses.

Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) started last trading at an opening price of $15.94 and during the session hit at $16.08 but when closing bell rang the stock finally advanced 0.13% to $15.85.

FURX traded with a volume of 29,614 shares, higher from average volume of 39,267 shares. The week-performance of the company after last close appeared at -1.98, 1 year performance moved at -5.09%, and year-to-date performance appeared positive with -5.15% while a month-performance after last trade went down at -2.46%.

Virtusa (VRTU) released its quarterly earnings data on Tuesday. The company announced $0.22 earnings a share for the quarter, surpassing the consensus forecast of $0.20 by $0.02. The company’s sales for the quarter rose 29.9% on a y-o-y basis.

Virtusa Corporation (NASDAQ:VRTU) commenced last trading with a price of $15.98 and rallied up to $16.01 during the day but finished the trade at $15.99 with a score of 1.20%.

Shares price of VRTU is ahead its 52 week low with 34.71 % and logging behind from its 52 week high price with -26.62%. VRTU stock price volatility for a week moved about 2.02%. In share capital VRTU has 25.71 million outstanding shares among them 22.65 million shares have been floated in market exchange. VRTU stock institutional ownership remained 80.49% while insider ownership included 7.08%.

Ultralife Corp. (NASDAQ:ULBI) began the last trading session with a price of $4.14 and throughout the session climbed at a high of $4.24 but when day-trade ended the stock finally advanced 0.24% to $4.17.

The liquidity measure in recent quarter results of the company was recorded 2.56 as current ration and on other hand debt to equity ratio and long-term debt to equity ratio was also remained flat. ULBI had a cash of $4.49 per share and a book value per share as $4.11 in the most recent quarter.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.